Evogene
EVGN
15 hedge funds and large institutions have $65.1M invested in Evogene in 2014 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0.34% more ownership
Funds ownership: 1.64% → 1.98% (+0.34%)
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
3% less capital invested
Capital invested by funds: $66.8M → $65.1M (-$1.72M)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$9.97M |
| 2 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
+$3.17M |
| 3 |
MTWSIF
Mivtachim The Workers Social Insurance Fund
Tel Aviv,
Israel
|
+$2.47M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$9.66K |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$4.42K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$2.47M |
| 2 |
JP Morgan Chase
New York
|
-$1.1M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$71.6K |
| 4 |
Citigroup
New York
|
-$37.3K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$23K |
EVGN Hedge Fund Activity: Q3 2014 in Review
15 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2014, worth a combined $65.1M — down 2.6% from $66.8M a quarter earlier.
Fund positioning in EVGN was balanced in Q3 2014: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 5 trimmed.
The largest buyer was Waddell & Reed Financial, adding an estimated $9.97M. The largest seller was Goldman Sachs, cutting an estimated $2.47M.
- 15 institutional investors held Evogene (EVGN) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $65.1M of Evogene stock for Q3 2014, down 2.6% quarter-over-quarter.
- 2 funds opened new Evogene positions in Q3 2014 and 2 closed out, a net change of 0 holders.
- The largest Evogene buyer in Q3 2014 was Waddell & Reed Financial, an estimated $9.97M added.
- The largest Evogene seller in Q3 2014 was Goldman Sachs, an estimated $2.47M sold.
Based on aggregated 13F filings for Q3 2014.